Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5056 to 5070 of 5124 results for technology

  1. NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis

    NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).

  2. NICE draft guidance recommends tucatinib for advanced breast cancer

    Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.

  3. NICE explores extending its use of data to inform its guidance

    Consultation on proposal open until Friday 13 September

  4. NICE signs agreement with Colombia's Institute of Health Technology Assessment to forge closer working ties

    Research and knowledge sharing key to collaborative working approach agreed the two agencies

  5. NICE signs up to join the GetReal Institute

    NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.

  6. NICE's methods of technology evaluation - presenting a case for change

    NICE has today (6 November 2020) launched a public consultation on proposals for changes to the methods it uses to develop its guidance on medicines, medical devices and diagnostics.

  7. NICE's processes of technology evaluation - presenting a case for change

    NICE has today (4 February 2021) launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies.

  8. NICE welcomes appointment of six new Board members

    NICE is delighted with today’s (15 March) announcement from the Department of Health & Social Care appointing six new non-executive directors to its Board following their approval by the Secretary of State.

  9. NICE welcomes life sciences review recommendations

    NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.

  10. Nine treatment options to be made available for adults with depression or an anxiety disorder

    Six digitally enabled therapies for adults with anxiety disorders and three for adults with depression have been recommended for use in the NHS while further data is gathered, NICE has said.

  11. Wireless device recommended for treating people with overactive bladder

    Axonics SNS has potential to save the NHS around £6,200 per patient if the device lasts more than six years

  12. Women with moderate to severe fibroids set to be offered new one-a-day treatment following final draft guidance from NICE

    Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended relugolix with estradiol and norethisterone acetate (also called Ryeqo and made by Gedeon Ritcher UK) in final draft guidance.

  13. A new approach to prioritising requests for NICE Scientific Advice

    Dr Jacoline Bouvy explains the new NICE Scientific Advice prioritisation process.

  14. A 'safe space' for addressing complex health technology assessment challenges

    Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.

  15. People with advanced or metastatic urothelial cancer to get life-extending treatment

    Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for a new life-extending treatment after NICE published final draft guidance today (30 September 2021) recommending atezolizumab.